Twenty-four-hour effects of bimatoprost 0.01% monotherapy on intraocular pressure and ocular perfusion pressure

Jonathan D Tung, Ali Tafreshi, Robert N Weinreb, J Rigby Slight, Felipe A Medeiros, John H K Liu, Jonathan D Tung, Ali Tafreshi, Robert N Weinreb, J Rigby Slight, Felipe A Medeiros, John H K Liu

Abstract

Objectives: To investigate the 24 h effects of bimatoprost 0.01% monotherapy on intraocular pressure (IOP) and ocular perfusion pressure (OPP).

Design: Prospective, open-label experimental study.

Setting: Single tertiary ophthalmic clinic.

Participants: Sixteen patients with diagnosed primary open-angle glaucoma (POAG) or ocular hypertension (ages, 49-77 years).

Interventions: Baseline data of 24 h IOP in untreated patients were collected in a sleep laboratory. Measurements of IOP were taken using a pneumatonometer every 2 h in the sitting and supine body positions during the 16 h diurnal/wake period and in the supine position during the 8 h nocturnal/sleep period. After baseline measurements were taken, patients were treated with bimatoprost 0.01% one time per day at bedtime for 4 weeks, and then 24 h IOP data were collected under the same laboratory conditions.

Primary and secondary outcome measures: Diurnal and nocturnal IOP and OPP means under bimatoprost 0.01% treatment were compared with baseline.

Results: The diurnal and nocturnal IOP means were significantly lower under the bimatoprost 0.01% treatment than baseline in both the sitting and supine positions. The diurnal and nocturnal OPP means were significantly higher under treatment than baseline in both the sitting and supine positions.

Conclusion: Bimatoprost 0.01% monotherapy significantly lowered IOP and increased OPP during the 24 h period.

Figures

Figure 1
Figure 1
Profiles of 24 h IOP in the habitual body positions. Measurements were taken from 16 subjects sitting during the diurnal period and supine during the nocturnal period. Open circles represent the baseline, and solid circles represent the bimatoprost 0.01% treatment for 4 weeks. Error bars represent standard error of the mean. IOP, intraocular pressure.
Figure 2
Figure 2
Profiles of 24 h supine IOP. Open circles represent the baseline, and solid circles represent the bimatoprost 0.01% treatment for 4 weeks. Data were from the same 16 subjects as in figure 1. Error bars represent standard error of the mean. IOP, intraocular pressure.

References

    1. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004;363:1711–20
    1. Weinreb RN, Harris A. Ocular blood flow in Glaucoma. WGA consensus series 6. Amsterdam, the Netherlands: Kugler Publications, 2009:59–128
    1. Medeiros FA, Brandt J, Liu J, et al. IOP as a risk factor for glaucoma development and progression. In: Weinreb RN, Brandt JD, Garway-Heath DF, et al. Intraocular pressure: reports and consensus statements of the 4th Global AIGS Consensus meeting on intraocular pressure. The Hague, The Netherlands: Kugler, 2007:59–74 WGA Consensus Series 4
    1. Bagga H, Liu JH, Weinreb RN. Intraocular pressure measurements throughout the 24 h. Curr Opin Ophthalmol 2009;20:79–83
    1. Orzalesi N, Rossetti L, Invernizzi T, et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000;41:2566–73
    1. Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol 2004;138:389–95
    1. Sit AJ, Weinreb RN, Crowston JG, et al. Sustained effect of travoprost on diurnal and nocturnal intraocular pressure. Am J Ophthalmol 2006;141:1131–3
    1. Liu JH, Medeiros FA, Slight JR, et al. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy. Ophthalmology 2009;116:449–54
    1. Liu JH, Medeiros FA, Slight JR, et al. Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure. Ophthalmology 2010;117:2075–9
    1. Woodward DF, Phelps RL, Krauss AH, et al. Bimatoprost: a novel antiglaucoma agent. Cardiovasc Drug Rev 2004;22:103–20
    1. Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol 2008;53(Suppl 1):S107–20
    1. Williams RD, Cohen JS, Gross RL, et al. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Br J Ophthalmol 2008;92:1387–92
    1. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma 2008;17:667–73
    1. Konstas AG, Katsimbris JM, Lallos N, et al. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology 2005;112:262–6
    1. Katz LJ, Cohen JS, Batoosingh AL, et al. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol 2010;149:661–71 e1
    1. Liu JH, Zhang X, Kripke DF, et al. Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. Invest Ophthalmol Vis Sci 2003;44:1586–90
    1. Liu JH, Kripke DF, Twa MD, et al. Twenty-four-hour pattern of intraocular pressure in the aging population. Invest Ophthalmol Vis Sci 1999;40:2912–7
    1. Mansouri K, Shaarawy T. Continuous intraocular pressure monitoring with a wireless ocular telemetry sensor: initial clinical experience in patients with open angle glaucoma. Br J Ophthalmol 2011;95:627–9
    1. Liu JH, Weinreb RN. Monitoring intraocular pressure for 24 h. Br J Ophthalmol 2011;95:599–600
    1. Liu JH, Gokhale PA, Loving RT, et al. Laboratory assessment of diurnal and nocturnal ocular perfusion pressures in humans. J Ocul Pharmacol Ther 2003;19:291–7
    1. Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci 2006;47:2917–23
    1. Nakamura T, Yamada M, Teshima M, et al. Electrophysiological characterization of tight junctional pathway of rabbit cornea treated with ophthalmic ingredients. Biol Pharm Bull 2007;30:2360–4
    1. Orzalesi N, Rossetti L, Bottoli A, et al. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology 2006;113:239–46
    1. Yildirim N, Sahin A, Gultekin S. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma. J Glaucoma 2008;17:36–9
    1. Quaranta L, Pizzolante T, Riva I, et al. Twenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucoma. Br J Ophthalmol 2008;92:1227–31
    1. Konstas AG, Hollo G, Mikropoulos D, et al. Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. Br J Ophthalmol 2010;94:209–13

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir